Floatz logo

Bxcl501

Acute Pain

Udayana UniversityPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Acute Pain cohort.

Asset / SponsorPhaseRating
NEPENTHE
Ondokuz Mayıs University
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Tanta University
Phase 4BBB
DEXAMETHASONE
Peking University Third Hospital
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
The Second Affiliated Hospital of Chongqing Medical University
Phase 4BB
LIDOCAINE
Peking University Third Hospital
Phase 4BB

View all 31 →

Same molecule, other indications

Bxcl501 is also rated in:

Pain, ChronicDormant
A
Indicative ·
80 / 100
View asset →
Agitation,PsychomotorDormant
A
Indicative ·
80 / 100
View asset →
schizophreniform disorderDormant
A
Indicative ·
80 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →